Thomas John Dietz - 22 Dec 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role: Director
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol: EIGR
Transactions as of: 22 Dec 2022
Transactions value $: -$26,303
Form type: 4
Date filed: 27 Dec 2022, 16:31
Previous filing: 02 Sep 2022
Next filing: 25 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Sale	-$26.3K	-22.5K	-51.72%	$1.17	21K	22 Dec 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1628 to $1.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1628 to $1.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.